At1.Ax
AT1.AX is a company in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of advanced medical equipment and technology solutions.
Business. AT1.AX is a company in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of advanced medical equipment and technology solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AT1.AX is a company in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of advanced medical equipment and technology solutions.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative approach to leverage. However, the company's liquidity position is assessed as medium, with a current ratio of 3.03, suggesting that it has sufficient current assets to cover its current liabilities, but with some room for improvement. The company's negative operating cash flow of -1,958,820 AUD and free cash flow of -3,422,260 AUD indicate a cash outflow from operations, which could be a concern for its short-term liquidity.
In terms of profitability, the company reported a net loss of -4,970,930 AUD, with a negative return on equity of -71.26% and a negative return on assets of -53.58%. These figures are significantly below the industry norms for profitability and returns, suggesting that the company is underperforming relative to its peers in the Advanced Medical Equipment & Technology industry.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no specific geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn or if there are regulatory changes that impact its operations.
The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The negative operating income of -4,954,250 AUD and the negative net income suggest that the company is not currently generating profits and may need to implement cost-cutting measures or increase revenue to improve its financial position.
The risk assessment indicates a medium liquidity risk, with the company having a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's financial performance and negative cash flows may necessitate additional financing, which could lead to dilution if new shares are issued.
Recent events and filings have not been provided in the available data, so there is no specific information on recent developments that may impact the company's financial position or strategic direction.
- The company has a low debt-to-equity ratio, indicating a conservative capital structure.
- The company is currently reporting a net loss and negative returns on equity and assets.
- The company's liquidity position is medium, with a current ratio of 3.03.
- The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
- The company's risk assessment indicates a medium liquidity risk and a low dilution risk.
- margin_outlook_rationale: The company's negative operating income and net loss suggest that its margins are currently under pressure, and there is no indication of improvement in the near term.
- rd_outlook_rationale: There is no specific information provided on the company's research and development activities or their expected impact on future performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- AT1.AX Market data — financials · 2026-05-27